Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in Routine Clinical Practice

被引：0

作者：

Goldberg, Stuart L. ^{[1
]}

Mauro, Michael J. ^{[2
]}

Cortes, Jorge E. ^{[3
]}

Keating, Scott Justin ^{[4
]}

Bhandari, Hitesh ^{[5
]}

Chen, Clara ^{[4
]}

机构：

[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[2] Mem Sloan Kettering Canc Ctr, Myeloproliferat Neoplasms Program, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[4] Bristol Myers Squibb, Princeton, NJ USA

[5] SmartAnalyst India Pvt Ltd, Gurgaon, India

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-128290

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4151

引用

页数：3

共 50 条

[31] Comparison of PACE clinical trial versus real-world (RW) ponatinib (PON) prescribing and duration of therapy (DOT) in US chronic-phase chronic myeloid leukemia (CP-CML) patients (pts).
Mauro, Michael J.
McGarry, Lisa
Yang, Mo
Lustgarten, Stephanie
Huang, Hui
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[32] Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs)
Le Coutre, Philipp D.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane F.
Khoury, H. Jean
Talpaz, Moshe
Dipersio, John F.
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Muller, Martin C.
Gambacorti-Passerini, Carlo
Lustgarten, Stephanie
Yanase, Kumiko
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy P.
Goldman, John M.
Shah, Neil P.
Kantarjian, Hagop M.
Cortes, Jorge E.
BLOOD, 2013, 122 (21)
[33] BCR-ABL Fluctuation Analysis in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients with MR 4.5
Pereira, Mariana Pinto
Vanelli, Tito
da Silva, Eduardo Gomes
Americo, Andre Dias
Burin, Mariana M.
Soares, Tahiane
Silla, Lucia
Daudt, Liane
Fogliatto, Laura
BLOOD, 2015, 126 (23)
[34] Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily
Shah, N. P.
Cortes, J. E.
Schiffer, C. A.
le Coutre, P.
Bahceci, E.
Lambert, A.
Saglio, G.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[35] Cytogenetic and molecular testing in patients with chronic myeloid leukemia (CML) in a prospective observational study (SIMPLICITY).
Goldberg, Stuart L.
Cortes, Jorge E.
Gambacorti-Passerini, Carlo
Hehlmann, Ruediger
Khoury, Hanna Jean
Mauro, Michael J.
Michallet, Mauricette
Paquette, Ronald
Simonsson, Bengt
Foreman, Aimee
Mohamed, Hesham
Subar, Milayna
Zyczynski, Teresa Maria
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[36] Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON).
Talpaz, Moshe
Cortes, Jorge E.
Kantarjian, Hagop M.
Shah, Neil P.
Bixby, Dale L.
Flinn, Ian
O'Hare, Thomas J.
Hu, Simin
Rivera, Victor M.
Clackson, Timothy Piers
Conlan, Maureen G.
Haluska, Frank G.
Druker, Brian J.
Deininger, Michael W. N.
Mauro, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[37] Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)
Lipton, Jeffrey H.
Chuah, Charles
Guerci-Bresler, Agnes
Rosti, Gianantonio
Simpson, David
Assouline, Sarit
Etienne, Gabriel
Nicolini, Franck E.
Le Coutre, Philipp
Clark, Richard
Stenke, Leif
Andorsky, David
Oehler, Vivian
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Haluska, Frank G.
Baccarani, Michele
Cortes, Jorge E.
Guilhot, Francois
Hochhaus, Andreas
Hughes, Timothy P.
Kantarjian, Hagop M.
Shah, Neil P.
Talpaz, Moshe
Deininger, Michael W.
BLOOD, 2014, 124 (21)
[38] Warning As Defiened By European Leukemia Net 2013 (ELN 2013) In Chronic Phase Chronic Myeloid Leukemia (CP-CML) Corresponds To Warning In The Clinical Practice?
Fogliatto, Laura
Capra, Marcelo
Shaan, Mariza
Costa, Tito Vanelli
Breunig, Raquel
Fraga, Christina G. S.
Torriani, Mayde Seadi
Silla, Lucia
Daudt, Liane Esteves
Fernandes, Mario Sergio
Almeida, Denise
Schilling, Marco Antonio
Hellwig, Tania
Fassina, Katia
Wisintainer, Sabrina
Moschen, Mariangela
Daltoe, Tiago
Zardo, Adriana
Kratochvil, Juliana
Fernandes, Viviane Magagnin
Eickhoff, Cheila
Nene, Moema
Ahmad, Saozan
Almeida, Andreia Dias
Lenz, Vitor
BLOOD, 2013, 122 (21)
[39] Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial
Kantarjian, Hagop M.
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
le Coutre, Philipp D.
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane F.
Khoury, H. Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Mueller, Martin C.
Gambacorti-Passerini, Carlo
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy P.
Goldman, John M.
Shah, Neil P.
BLOOD, 2013, 122 (21)
[40] Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving dasatinib 100mg once daily
Le Coutre, P.
Shah, N.
Cortes, J. E.
Schiffer, C.
Bahceci, E.
Lambert, A.
Saglio, G.
ONKOLOGIE, 2010, 33 : 82 - 82

← 1 2 3 4 5 →